Bank of New York Mellon Corp Acquires New Stake in Immunovant, Inc. $IMVTMarket Beat·23 hours agoIMVT-1.03%
The Hidden Corners of the Market: Psychedelics, Data Centers, and the Micro-Catalyst EconomyGlobal Report·1 day ago, 10:13 AMEM0.00%CCHH+0.81%
Immunovant director Atul Pande disposes of 1,500 common shares worth $64,905PUBT·Aug 28 at 08:29 PMIMVT-1.03%
Kuehn Law Encourages Investors of Immunovant, Inc. to Contact Law FirmPR Newswire·Aug 19 at 11:52 PMIMVT-1.03%
IMVT: IMVT-1402 targets major autoimmune diseases with best-in-class efficacy and broad clinical reachQuartr·Aug 6 at 11:55 AMIMVT-1.03%
Immunovant FY27 Q1 net loss widens 27% to $153.2 million; R&D expenses rise 40.9% to $142.6 millionPUBT·Aug 6 at 11:20 AMIMVT-1.03%
Roivant President, Immunovant CEO Eric Venker sells USD 6.99 million in common sharesPUBT·Jul 30 at 01:00 AMIMVT-1.03%ROIV-0.98%
